Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.
Che M, Chaturvedi A, Munro SA, Pitzen SP, Ling A, Zhang W, Mentzer J, Ku SY, Puca L, Zhu Y, Bergman AM, Severson TM, Forster C, Liu Y, Hildebrand J, Daniel M, Wang TY, Selth LA, Hickey T, Zoubeidi A, Gleave M, Bareja R, Sboner A, Tilley W, Carroll JS, Tan W, Kohli M, Yang R, Hsieh AC, Murugan P, Zwart W, Beltran H, Huang RS, Dehm SM. Che M, et al. Among authors: puca l. Nat Commun. 2021 Nov 4;12(1):6377. doi: 10.1038/s41467-021-26612-1. Nat Commun. 2021. PMID: 34737261 Free PMC article.
An emerging role for cytopathology in precision oncology.
Pauli C, Puca L, Mosquera JM, Robinson BD, Beltran H, Rubin MA, Rao RA. Pauli C, et al. Among authors: puca l. Cancer Cytopathol. 2016 Mar;124(3):167-73. doi: 10.1002/cncy.21647. Epub 2015 Dec 7. Cancer Cytopathol. 2016. PMID: 26641771 Free article.
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, Sboner A, Garraway LA, Rubin MA, Demichelis F. Beltran H, et al. Among authors: puca l. Nat Med. 2016 Mar;22(3):298-305. doi: 10.1038/nm.4045. Epub 2016 Feb 8. Nat Med. 2016. PMID: 26855148 Free PMC article.
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T, Cheung C, Yuen KS, Gao D, Chen Y, Eilers M, Mosquera JM, Robinson BD, Elemento O, Rubin MA, Demichelis F, Rickman DS. Dardenne E, et al. Among authors: puca l. Cancer Cell. 2016 Oct 10;30(4):563-577. doi: 10.1016/j.ccell.2016.09.005. Cancer Cell. 2016. PMID: 27728805 Free PMC article.
Emerging Variants of Castration-Resistant Prostate Cancer.
Vlachostergios PJ, Puca L, Beltran H. Vlachostergios PJ, et al. Among authors: puca l. Curr Oncol Rep. 2017 May;19(5):32. doi: 10.1007/s11912-017-0593-6. Curr Oncol Rep. 2017. PMID: 28361223 Free PMC article. Review.
Patient derived organoids to model rare prostate cancer phenotypes.
Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, Churakova Y, Cheung C, Deonarine LD, McNary TJ, Rosati R, Tagawa ST, Nanus DM, Mosquera JM, Sawyers CL, Chen Y, Inghirami G, Rao RA, Grandori C, Elemento O, Sboner A, Demichelis F, Rubin MA, Beltran H. Puca L, et al. Nat Commun. 2018 Jun 19;9(1):2404. doi: 10.1038/s41467-018-04495-z. Nat Commun. 2018. PMID: 29921838 Free PMC article.
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST. Beltran H, et al. Among authors: puca l. Clin Cancer Res. 2019 Jan 1;25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912. Epub 2018 Sep 19. Clin Cancer Res. 2019. PMID: 30232224 Free PMC article. Clinical Trial.
ONECUT2 is a driver of neuroendocrine prostate cancer.
Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH. Guo H, et al. Among authors: puca l. Nat Commun. 2019 Jan 17;10(1):278. doi: 10.1038/s41467-018-08133-6. Nat Commun. 2019. PMID: 30655535 Free PMC article.
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L, Pan H, Motanagh S, Hess J, Donoghue AJ, Sboner A, Wang Y, Dittamore R, Rickman D, Nanus DM, Tagawa ST, Elemento O, Mosquera JM, Saunders L, Beltran H. Puca L, et al. Sci Transl Med. 2019 Mar 20;11(484):eaav0891. doi: 10.1126/scitranslmed.aav0891. Sci Transl Med. 2019. PMID: 30894499 Free PMC article. Clinical Trial.
34 results